Jayson Bedford
Stock Analyst at Raymond James
(3.96)
# 618
Out of 5,176 analysts
324
Total ratings
55.43%
Success rate
7.84%
Average return
Main Sectors:
Stocks Rated by Jayson Bedford
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AXGN Axogen | Maintains: Outperform | $20 → $27 | $33.28 | -18.87% | 2 | Oct 30, 2025 | |
| ISRG Intuitive Surgical | Maintains: Outperform | $592 → $603 | $469.98 | +28.30% | 9 | Oct 22, 2025 | |
| CBLL CeriBell | Initiates: Strong Buy | $19 | $18.77 | +1.23% | 1 | Oct 21, 2025 | |
| ABT Abbott Laboratories | Maintains: Outperform | $141 → $146 | $104.83 | +39.27% | 30 | Oct 16, 2025 | |
| JNJ Johnson & Johnson | Maintains: Outperform | $174 → $209 | $239.93 | -12.89% | 24 | Oct 15, 2025 | |
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $104 → $113 | $87.64 | +28.94% | 9 | Aug 8, 2025 | |
| ICUI ICU Medical | Maintains: Strong Buy | $187 → $180 | $131.38 | +37.01% | 22 | Aug 8, 2025 | |
| MMSI Merit Medical Systems | Maintains: Outperform | $108 → $102 | $68.11 | +49.76% | 28 | Jul 31, 2025 | |
| DXCM DexCom | Maintains: Strong Buy | $99 → $102 | $66.84 | +52.60% | 31 | Jul 31, 2025 | |
| BSX Boston Scientific | Maintains: Strong Buy | $121 → $124 | $69.78 | +77.70% | 26 | Jul 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $328 → $360 | $216.00 | +66.67% | 27 | May 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $204 → $185 | $178.09 | +3.88% | 7 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $275 → $270 | $158.27 | +70.59% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $12 → $10 | $11.22 | -10.87% | 14 | Jan 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $227 → $271 | $108.18 | +150.51% | 12 | Dec 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $13.86 | - | 10 | Nov 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $24.26 | - | 13 | Apr 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $82.67 | - | 20 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $17.12 | - | 6 | Jan 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $87.89 | - | 14 | Aug 24, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $6.76 | - | 4 | Mar 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $75 → $86 | $75.52 | +13.88% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.16 | - | 5 | Aug 2, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $9.56 | - | 3 | Jan 2, 2018 |
Axogen
Oct 30, 2025
Maintains: Outperform
Price Target: $20 → $27
Current: $33.28
Upside: -18.87%
Intuitive Surgical
Oct 22, 2025
Maintains: Outperform
Price Target: $592 → $603
Current: $469.98
Upside: +28.30%
CeriBell
Oct 21, 2025
Initiates: Strong Buy
Price Target: $19
Current: $18.77
Upside: +1.23%
Abbott Laboratories
Oct 16, 2025
Maintains: Outperform
Price Target: $141 → $146
Current: $104.83
Upside: +39.27%
Johnson & Johnson
Oct 15, 2025
Maintains: Outperform
Price Target: $174 → $209
Current: $239.93
Upside: -12.89%
Zimmer Biomet Holdings
Aug 8, 2025
Maintains: Outperform
Price Target: $104 → $113
Current: $87.64
Upside: +28.94%
ICU Medical
Aug 8, 2025
Maintains: Strong Buy
Price Target: $187 → $180
Current: $131.38
Upside: +37.01%
Merit Medical Systems
Jul 31, 2025
Maintains: Outperform
Price Target: $108 → $102
Current: $68.11
Upside: +49.76%
DexCom
Jul 31, 2025
Maintains: Strong Buy
Price Target: $99 → $102
Current: $66.84
Upside: +52.60%
Boston Scientific
Jul 24, 2025
Maintains: Strong Buy
Price Target: $121 → $124
Current: $69.78
Upside: +77.70%
May 27, 2025
Maintains: Outperform
Price Target: $328 → $360
Current: $216.00
Upside: +66.67%
May 7, 2025
Maintains: Outperform
Price Target: $204 → $185
Current: $178.09
Upside: +3.88%
Aug 2, 2024
Maintains: Outperform
Price Target: $275 → $270
Current: $158.27
Upside: +70.59%
Jan 9, 2024
Maintains: Outperform
Price Target: $12 → $10
Current: $11.22
Upside: -10.87%
Dec 20, 2023
Maintains: Outperform
Price Target: $227 → $271
Current: $108.18
Upside: +150.51%
Nov 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $13.86
Upside: -
Apr 24, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $24.26
Upside: -
Feb 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $82.67
Upside: -
Jan 5, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $17.12
Upside: -
Aug 24, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $87.89
Upside: -
Mar 5, 2021
Downgrades: Underperform
Price Target: n/a
Current: $6.76
Upside: -
Nov 5, 2020
Maintains: Outperform
Price Target: $75 → $86
Current: $75.52
Upside: +13.88%
Aug 2, 2019
Downgrades: Market Perform
Price Target: n/a
Current: $1.16
Upside: -
Jan 2, 2018
Downgrades: Market Perform
Price Target: n/a
Current: $9.56
Upside: -